; (B) the sourcing of all component parts; (C) the sourcing of any active pharmaceutical ingredients; and (D) the use of any scarce raw materials; and (2) any other information determined by the Secretary to be relevant to the security of the supply chain of the drug or device. . (b) Provision of additional information Section 506C–1 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356c–1 ) is amended— (1) in the heading, by striking drug shortages and inserting drug or device shortages ; (2) by striking drug shortages each place it appears and inserting drug or device shortages ; (3) in subsection (a)— (A) in paragraph (3)(B)— (i) in clause (i), by striking section 506C(g)(1) and inserting paragraph (1) or (2) of section 506C(g) ; and (ii) in clause (ii), by striking section 506C(g)(2) and inserting section 506C(g)(3) ; and (B) in paragraph (5), by striking drug shortage and inserting drug or device shortage ; and (4) in subsection (c), by striking drug shortage or .